MIOTOMADA BIOKIMYOVIY TAHLILLAR VA ULARNING O’ZGARISH DINAMIKASI

Authors

  • Amanbayeva Sanobar Sirojidinovna, Abdulaziz Xabibullayev Xamidullo o’g’li Qo‘qon universiteti Andijon filiali

Keywords:

Miotoma, biokimyoviy markerlar, kreatin kinaza (CK), miyoglobin, laktat dehidrogenaza (LDH), aminotransferazalar, microRNA, neyrofilamentlar, mushak shikastlanishi, laborator tahlil, monitoring, terapiya

Abstract

Miotomalar — bu skelet mushaklarini zararlovchi kasalliklar guruhi bo‘lib, ularning asosida genetik, metabolik yoki yallig‘lanishli omillar yotadi. Ushbu kasalliklarda mushak tolalarida strukturaviy o‘zgarishlar, hujayra ichidagi energetik va biokimyoviy muvozanatning buzilishi kuzatiladi. Biokimyoviy tahlillar — kasallik kechishini baholash va davolash samaradorligini monitoring qilishning asosiy vositasi hisoblanadi. Maqolada kreatin kinaza (CK), miyoglobin, laktat dehidrogenaza (LDH), aminotransferazalar, microRNA, neyrofilamentlar va immunologik markerlarning dinamik o‘zgarishi tahlil qilindi. Tadqiqotlar shuni ko‘rsatadiki, CK va miyoglobin faollashgan davrda keskin oshadi, davolash bosqichida esa asta-sekin pasayadi. Yangi biomarkerlar esa erta diagnostika va terapiyaga javobni baholashda muhim ahamiyatga ega. Biokimyoviy monitoringni klinik belgilar va instrumental tahlillar bilan birgalikda olib borish diagnostik aniqlikni oshiradi va davolash natijasini yaxshiroq baholash imkonini beradi.

References

Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71:e127–e248.

Unger T., Borghi C., Charchar F., et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–1357.

Carey R.M., Muntner P., Bosworth H.B., et al. Resistant Hypertension: Detection, Evaluation, and Management. Hypertension. 2018;72:804–818.

Kario K., Wang J.G., Chen C.H. Clinical Implications of Blood Pressure Variability in Hypertension and Cardiovascular Risk. Journal of Clinical Hypertension. 2021;23:1001–1012.

Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39:3021–3104.

Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387:957–967.

Carey R.M., Whelton P.K. Prevention, Detection, Evaluation, and Management of High Blood Pressure: A Review. JAMA. 2018;320:199–204.

Muntner P., Hardy S.T., Fine L.J., et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999–2018. JAMA. 2020;324:1190–1200.

Biff F., Townsend R., Rajzer M., et al. Innovative biomarkers and early detection strategies in hypertension. Journal of Hypertension Research. 2022;40:12–25.

Carey R.M., Calhoun D.A., Bakris G.L., et al. Resistant Hypertension: Updated Consensus and Management Strategies. Hypertension. 2019;74:1339–1353.

Downloads

Published

2026-06-03